Supplementary Materials

Supplementary Material for:

Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques

Diogo M. Magnani, Thomas F. Rogers, Nathan Beutler, Michael J. Ricciardi, Varian K. Bailey, Lucas Gonzalez-Nieto, Bryan Briney, Devin Sok, Khoa Le, Alexander Strubel, Martin J. Gutman, Núria Pedreño-Lopez, Nathan D. Grubaugh, Cassia G. T. Silveira, Helen S. Maxwell, Aline Domingues, Mauricio A. Martins, David E. Lee, Erica E. Okwuazi, Sherrie Jean, Elizabeth A. Strobert, Ann Chahroudi, Guido Silvestri, Thomas H. Vanderford, Esper G. Kallas, Ronald C. Desrosiers, Myrna C. Bonaldo, Stephen S. Whitehead, Dennis R. Burton,* David I. Watkins*

*Corresponding author. Email: burton{at}scripps.edu (D.R.B.); dwatkins{at}med.miami.edu (D.I.W.)

Published 4 October 2017, Sci. Transl. Med. 9, eaan8184 (2017)
DOI: 10.1126/scitranslmed.aan8184

This PDF file includes:

  • Fig. S1. Plasmablast-derived human mAbs neutralize ZIKV in vitro.
  • Fig. S2. Epitope mapping: SMZAb1, SMZAb2, and SMZAb5 ZIKV E protein epitope specificity was evaluated.
  • Fig. S3. Binding of SMZAb1, SMZAb2, and SMZAb5 to whole ZIKV or DENV was evaluated by virus capture ELISA using 4G2.
  • Fig. S4. DENV neutralization by SMZAbs.
  • Fig. S5. ZIKV-neutralizing activity after mAb infusion (FRNT).
  • Table S1. SMZAb amino acid sequences.
  • Table S2. Neutralization of ZIKV strains and DENV serotypes by SMZAbs (FRNT50 μg ml−1).
  • Table S3. ZIKV Paraiba/2015 neutralization by SMZAbs before infusion.
  • Table S4. Study animals.
  • Table S5. Viral titers (log10 PFU ml−1) in serum after ZIKV challenge.
  • Table S6. Viral titers (vRNA copies ml−1) in serum after ZIKV challenge.

[Download PDF]